Nature of the Business and Going Concern (Details)			6 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares	May 15, 2020 USD ($)	Jun. 30, 2021 USD ($) product segment	Jan. 27, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 19, 2020 employee	Dec. 13, 2018 USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of topical generic products with approvals			39
Number of discounted products			3
Pharmaceutical products, number of products with paused marketing and sale			5
Pharmaceutical products, number of products being examined for potential discontinuance			5
Segments | segment			1
Cash and cash equivalents | $	$ 27,500,000		$ 22,626,000		$ 5,946,000	$ 5,851,000
Aggregate principal amount | $			$ 111,882,000		$ 181,580,000
Number of terminated employees | employee							53
Number of furloughed employees | employee							15
Proceeds received under PPP | $		$ 3,400,000
Stated interest rate		1.00%
Minimum
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of products being examined for potential discontinuance, examination period			12 months
Maximum
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of products being examined for potential discontinuance, examination period			24 months
United States
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of generic products marketed			37
Pharmaceutical products, number of branded generic products marketed			1
Number of Abbreviated New Drug Applications on topical products			7
Number of New Drug Application Prior Approval Supplements for sterile injectable products, awaiting approval			3
Ophthalmic products, number of generic injectable products marketed			24
Ophthalmic products, number of generic topical products marketed			1
Ophthalmic products, number of generic products marketed			3
Canada
Summary of Significant Accounting Policies Details [Line Items]
Number of Abbreviated New Drug Applications on topical products			1
At-the-Market Offering
Summary of Significant Accounting Policies Details [Line Items]
Stock issued during period, shares, new issues (in shares) | shares	38,712,036
Sale of stock, price per share (usd per share) | $ / shares	$ 0.993
Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $			$ 86,600,000
Term Loan | Line of Credit
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $								$ 80,000,000.0
Term Loan | Line of Credit | Delayed Draw Term Loan C
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $			$ 4,600,000	$ 4,600,000